Drug Trial Radar · NCT01000974
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
Last checked: Nov 19, 2026Latest source record: Jul 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,003
Actual
Start
Jun 18, 2010
Primary completion
Nov 18, 2011
Study completion Jul 17, 2013
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 weeks, up to 12 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, to demonstrate lot-to-lot consistency of the vaccine, to address the relevant concomitant vaccine administrations and to provide a comparison between GSK Biologicals' Hib conjugate vaccine and the licensed monovalent Hib vaccine ActHIB as well as the licensed combination product Pentacel in infants at 2, 4, 6 and 15-18 months of age. This study is designed with a primary and a booster phase.
Conditions
- Haemophilus Influenzae Type b
Interventions
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)Biological
Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
ActHIB™Biological
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Pentacel™Biological
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Pediarix™Biological
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Prevnar 13™Biological
Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Rotarix™Biological
Two oral doses in primary epoch at 2 and 4 months of age
Engerix™-BBiological
Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
Infanrix™Biological
One dose in the booster epoch at 15-18 months of age as intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mLTime frame: At 1 month after last dose of primary vaccination
- Number of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations ≥ 0.1 International Units Per Milliliter (IU/mL)Time frame: At 1 month after last dose of primary vaccination
- Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody ConcentrationsTime frame: At 1 month after last dose of primary vaccination
- Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody ConcentrationsTime frame: At 1 month after last dose of primary vaccination
- Anti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody ConcentrationsTime frame: At 1 month after last dose of primary vaccination
- Number of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA)Time frame: At 1 month after last dose of primary vaccination
- Number of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off ValueTime frame: At 1 month after last dose of primary vaccination
- Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mLTime frame: At 1 month after booster vaccination
Locations
63 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Dothan, Alabama
GSK Investigational Site
Benton, Arkansas
GSK Investigational Site
Fayetteville, Arkansas
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Antioch, California
GSK Investigational Site
Daly City, California
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Fremont, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Hayward, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Redwood City, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Santa Clara, California
GSK Investigational Site
Santa Rosa, California
GSK Investigational Site
Vallejo, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
West Covina, California
GSK Investigational Site
Boulder, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Orange City, Florida
GSK Investigational Site
Marietta, Georgia
GSK Investigational Site
Woodstock, Georgia
GSK Investigational Site
Honolulu, Hawaii
GSK Investigational Site
Waipio, Hawaii
GSK Investigational Site
Nampa, Idaho
GSK Investigational Site
Bardstown, Kentucky
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Fall River, Massachusetts
GSK Investigational Site
Stevensville, Michigan
GSK Investigational Site
Saint Paul, Minnesota
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Mineola, New York
GSK Investigational Site
Syracuse, New York
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.